FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560138732> ?p ?o ?g. }

• W2560138732 endingPage "1368" @default.
• W2560138732 startingPage "1354" @default.
• W2560138732 abstract "// Yan Dai 1 , Shiguang Jin 2, 3 , Xueping Li 4 , Daxin Wang 2, 3 1 The Second Xiangya Hospital of Central South University, Changsha, China 2 Clinical Medical College, Yangzhou University, Yangzhou, China 3 Medical Research Centre, Northern Jiangsu People’s Hospital, Yangzhou, China 4 Nanjing Hospital Affiliated to Nanjing Medical University, The First Hospital of Nanjing, Nanjing, China Correspondence to: Daxin Wang, email: daxinw2002@sina.com Xueping Li, email: lixueping6504@163.com Keywords: cisplatin, Bcl-2, AKT, epithelial ovarian cancer, drug resistance Received: August 02, 2016      Accepted: November 08, 2016      Published: December 07, 2016 ABSTRACT Many studies involving patients with cisplatin-resistant ovarian cancer have shown that AKT activation leads to inhibition of apoptosis. The aim of this study was to examine the potential involvement of the Bcl-2 family proteins in AKT-regulated cell survival in response to cisplatin treatment. Cisplatin-sensitive (PEO1) and cisplatin-resistant (PEO4) cells were taken from ascites of patients with ovarian cancer before cisplatin treatment and after development of chemoresistance. It was found that cisplatin treatment activated the AKT signaling pathway and promoted cell proliferation in cisplatin-resistant EOC cells. When AKT was transfected into nucleus of cisplatin-resistant ovarian cancer cells, DNA-PK was phosphorylated at S473. The activated AKT (pAKT-S473) in these cells inhibited the death signal induced by cisplatin thereby inhibiting cisplatin-mediated apoptosis. Results from this study showed that the combination of cisplatin, DNA-PK inhibitor NU7441, and AKT inhibitor TCN can overcome drug resistance, increase apoptosis, and re-sensitize PEO4 cells to cisplatin treatment. A decrease in apoptotic activity was seen in PEO4 cells when Bad was downregulated by siRNA, which indicated that Bad promotes apoptosis in PEO4 cells. Use of the Bcl-2 inhibitor ABT-737 showed that ABT-737 binds to Bcl-2 but not Mcl-1 and releases Bax/Bak which leads to cell apoptosis. The combination of ABT-737 and cisplatin leads to a significant increase in the death of PEO1 and PEO4 cells. All together, these results indicate that Bcl-2 family proteins are regulators of drug resistance. The combination of cisplatin and Bcl-2 family protein inhibitor could be a strategy for the treatment of cisplatin-resistant ovarian cancer." @default.
• W2560138732 created "2016-12-16" @default.
• W2560138732 creator A5001007694 @default.
• W2560138732 creator A5007909059 @default.
• W2560138732 creator A5047011210 @default.
• W2560138732 creator A5055364261 @default.
• W2560138732 date "2016-12-07" @default.
• W2560138732 modified "2023-10-15" @default.
• W2560138732 title "The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer" @default.
• W2560138732 cites W1688621929 @default.
• W2560138732 cites W1997788846 @default.
• W2560138732 cites W1999224816 @default.
• W2560138732 cites W2003049757 @default.
• W2560138732 cites W2008715871 @default.
• W2560138732 cites W2009158642 @default.
• W2560138732 cites W2027395744 @default.
• W2560138732 cites W2052902650 @default.
• W2560138732 cites W2080389159 @default.
• W2560138732 cites W2088845519 @default.
• W2560138732 cites W2089198306 @default.
• W2560138732 cites W2104682444 @default.
• W2560138732 cites W2106771830 @default.
• W2560138732 cites W2115268409 @default.
• W2560138732 cites W2115954319 @default.
• W2560138732 cites W2118744456 @default.
• W2560138732 cites W2127619043 @default.
• W2560138732 cites W2142215602 @default.
• W2560138732 cites W2143254803 @default.
• W2560138732 cites W2316996536 @default.
• W2560138732 cites W4212835986 @default.
• W2560138732 cites W4241297146 @default.
• W2560138732 doi "https://doi.org/10.18632/oncotarget.13817" @default.
• W2560138732 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6996903" @default.
• W2560138732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32064052" @default.
• W2560138732 hasPublicationYear "2016" @default.
• W2560138732 type Work @default.
• W2560138732 sameAs 2560138732 @default.
• W2560138732 citedByCount "60" @default.
• W2560138732 countsByYear W25601387322017 @default.
• W2560138732 countsByYear W25601387322018 @default.
• W2560138732 countsByYear W25601387322019 @default.
• W2560138732 countsByYear W25601387322020 @default.
• W2560138732 countsByYear W25601387322021 @default.
• W2560138732 countsByYear W25601387322022 @default.
• W2560138732 countsByYear W25601387322023 @default.
• W2560138732 crossrefType "journal-article" @default.
• W2560138732 hasAuthorship W2560138732A5001007694 @default.
• W2560138732 hasAuthorship W2560138732A5007909059 @default.
• W2560138732 hasAuthorship W2560138732A5047011210 @default.
• W2560138732 hasAuthorship W2560138732A5055364261 @default.
• W2560138732 hasBestOaLocation W25601387321 @default.
• W2560138732 hasConcept C121608353 @default.
• W2560138732 hasConcept C126322002 @default.
• W2560138732 hasConcept C143998085 @default.
• W2560138732 hasConcept C185592680 @default.
• W2560138732 hasConcept C190283241 @default.
• W2560138732 hasConcept C2776694085 @default.
• W2560138732 hasConcept C2778239845 @default.
• W2560138732 hasConcept C2780427987 @default.
• W2560138732 hasConcept C502942594 @default.
• W2560138732 hasConcept C55493867 @default.
• W2560138732 hasConcept C71924100 @default.
• W2560138732 hasConcept C75217442 @default.
• W2560138732 hasConcept C86554907 @default.
• W2560138732 hasConcept C98274493 @default.
• W2560138732 hasConceptScore W2560138732C121608353 @default.
• W2560138732 hasConceptScore W2560138732C126322002 @default.
• W2560138732 hasConceptScore W2560138732C143998085 @default.
• W2560138732 hasConceptScore W2560138732C185592680 @default.
• W2560138732 hasConceptScore W2560138732C190283241 @default.
• W2560138732 hasConceptScore W2560138732C2776694085 @default.
• W2560138732 hasConceptScore W2560138732C2778239845 @default.
• W2560138732 hasConceptScore W2560138732C2780427987 @default.
• W2560138732 hasConceptScore W2560138732C502942594 @default.
• W2560138732 hasConceptScore W2560138732C55493867 @default.
• W2560138732 hasConceptScore W2560138732C71924100 @default.
• W2560138732 hasConceptScore W2560138732C75217442 @default.
• W2560138732 hasConceptScore W2560138732C86554907 @default.
• W2560138732 hasConceptScore W2560138732C98274493 @default.
• W2560138732 hasIssue "1" @default.
• W2560138732 hasLocation W25601387321 @default.
• W2560138732 hasLocation W25601387322 @default.
• W2560138732 hasLocation W25601387323 @default.
• W2560138732 hasLocation W25601387324 @default.
• W2560138732 hasOpenAccess W2560138732 @default.
• W2560138732 hasPrimaryLocation W25601387321 @default.
• W2560138732 hasRelatedWork W1723369229 @default.
• W2560138732 hasRelatedWork W2053306150 @default.
• W2560138732 hasRelatedWork W2070783513 @default.
• W2560138732 hasRelatedWork W2257639774 @default.
• W2560138732 hasRelatedWork W2357943637 @default.
• W2560138732 hasRelatedWork W2916964185 @default.
• W2560138732 hasRelatedWork W3116479654 @default.
• W2560138732 hasRelatedWork W3183179750 @default.
• W2560138732 hasRelatedWork W4205189596 @default.
• W2560138732 hasRelatedWork W4385496679 @default.
• W2560138732 hasVolume "8" @default.
• W2560138732 isParatext "false" @default.

• next